Stopping muscular dystrophy with a ‘backup’ protein
Combining techniques used to deliver COVID vaccines, a new use of gene editing might stop or even reverse progression of Duchenne muscular dystrophy.
A new use of CRISPR gene editing halted and even reversed the progression of a model of Duchene muscular dystrophy in mice, according to work led by scientists at the Perelman School of Medicine of the University of Pennsylvania. The technique boosted a protein, utrophin, as a stand-in to take on the job of a different protein, dystrophin, which helps maintain healthy muscles and is in short supply in those with muscular dystrophy. This work was published in Molecular Therapy Advances.
“Unfortunately, there are currently no safe and effective therapies that can cure Duchenne muscular dystrophy, or even treat everyone with the disease equally,” said senior author Tejvir S. Khurana, MD, PhD, a professor of Physiology and a member of the Pennsylvania Muscle Institute. “But we believe that combining a pair of delivery systems already in use has great therapeutic potential and could lead to a significant change in how we treat this disease.”
The backup quarterback
Duchenne muscular dystrophy affects roughly one in 5,000 children and typically leads to their death in their 20s. It is caused by a mutation in the DMD gene, which is responsible for creating the dystrophin protein and its associated partner proteins. Without these proteins present to maintain and repair muscles during typical movements, muscle cells break down, turning to scar tissue. That results in progressive weakening and loss of muscles all over the body.
However, in the absence of dystrophin, a significant amount of utrophin can actually take over what dystrophin is usually tasked with.
“I like to give the analogy of utrophin’s role being like a backup quarterback: If the starting quarterback is injured, the backup can still lead the team to victory,” Khurana said. “That’s a bit like what we think we can do here.”
The issue has been how to get enough utrophin produced to adequately stand in.
A new but familiar delivery method
Khurana and his team decided to use different systems to edit the utrophin gene. A new type of viral vector called MyoAAV because they are better at targeting muscle cells and are less likely to be toxic. They also used the same kind of system that was first used for the COVID-19 vaccines to synthesize the mRNA cargo for CRISPR-Cas9 editing of the utrophin gene to dramatically increase utrophin protein production.
This system that Khurana and his team used combined the expertise of Drew Weissman, MD, PhD, the Roberts Family Professor in Vaccine Research, who won the Nobel Prize in 2023 for his work in developing mRNA systems that code the body cells to produce certain proteins, and that of Michael Mitchell, PhD, the Hibbert Professor of Bioengineering, who developed a delivery system that uses fatty compounds—called lipid nanoparticles—to encase and bring cargo to targeted cells.
Halting progression and possibly recovery
Within mouse models of Duchenne muscular dystrophy that received the treatment, there were signals of muscles increasing their force and improving their resistance to contraction, both of which are diminished in muscular dystrophy patients.
The researchers also noted a reduction in certain diseased fibers that are associated with Duchenne muscular dystrophy in mouse models.
“We designed our experiments to test for prevention of progression of the disease, but it’s possible that it could rescue or reverse damaged muscle cells,” Khurana said. “If a sufficient number of nuclei are edited in a damaged muscle cell there is no theoretical limitation for utrophin to rescue the entire damaged muscle since, over time, the newly expressed protein would not be restricted to the nuclei.”
Moving forward, Khurana and colleagues from Penn Medicine and Children’s Hospital of Philadelphia are working on new and different forms of gene editing that could be more precise and efficient in addressing utrophin production. They’re also testing other potential delivery methods for the treatment.
This work was supported partially by a grant from the Muscular Dystrophy Association (USA).
“These findings represent an encouraging step in exploring new approaches to Duchenne muscular dystrophy and highlight the importance of continued research to advance potential treatments for the community,” said Angela Lek, PhD, chief research officer of the Muscular Dystrophy Association. “This is an example of how important it is to continue support of research that builds and improves upon itself over time, as it further explores Dr. Khurana’s earlier work identifying utrophin as a potential therapeutic target.”
Media contact
Frank Otto
C: 267-693-2999
Francis.Otto@pennmedicine.upenn.edu
For Media Queries & Requests (24/7): 215-662-2560